

AVANTAGE - Therapeutic strategies including Avastin as 1st line therapy in elderly patients suffering from advanced (IIIB/IV Stage) non-squamous non-small cell lung cancer, in routine clinical practice

Head :Medical data center

Last update : 02/04/2022 | Version : 1 | ID : 74114

General

Identification

Detailed name Therapeutic strategies including Avastin as 1st line therapy in elderly patients suffering from advanced (IIIB/IV Stage) non-squamous non-small cell lung cancer, in routine clinical practice

Sign or acronym AVANTAGE

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation

ML28621

General Aspects

Medical area Cancer research

Study in connection with Covid-19 No

Pathology (details) Non-squamous non-small cell lung cancer

Health determinants Medicine

Keywords Bevacizumab

Scientific investigator(s) (Contact)

Name of the director Medical data center

Email data_sharing_france@roche.com

Organization Roche SAS

Collaborations

Participation in projects, networks and consortia No

Funding

Funding status Private

Governance of the database

Sponsor(s) or organisation(s) responsible Roche SAS

Organisation status Private

Presence of scientific or steering committees Yes

Additional contact

Main features

Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is carried out as part of an interventional study No

Database objective

Main objective

In each cohort of patients defined by their age classification ([65; 70[and ≥ 70 years), outcome measures are as follows:

- Antineoplastic agents combined with bevacizumab as 1st line therapy
- Classes of antineoplastic agents combined with bevacizumab as 1st line therapy (platinum salt, taxanes,...)
- Supportive care (growth factors, analgesics).

to describe:

- Characteristics of advanced nsNSCLC patients treated with bevacizumab as first-line therapy, and their disease characteristics,
- Progression-Free Survival (PFS) and Overall Survival (OS),
- Evolution of patients' quality of life over the treatment period with bevacizumab as first-line therapy,
- Safety of bevacizumab,

- Reasons for non-use of bevacizumab as first-line therapy in patients suffering from advanced nsNSCLC.

Inclusion criteria

Inclusion criteria :

- Patient aged \geq 65 years,
- Diagnosed with advanced nsNSCLC (stage IIIB or IV),
- For whom the physician has decided to initiate a treatment with bevacizumab combined with chemotherapy as 1st line therapy,
- Having received oral and written information about the study, and having signed a written consent form.

Population type

Age

Elderly (65 to 79 years)
Great age (80 years and more)

Population covered

Sick population

Pathology

C00-C75 - Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue

Gender

Male
Woman

Geography area

National

Data collection

Dates

Date of first collection (YYYY or MM/YYYY)

2013

Date of last collection (YYYY or MM/YYYY)

2017

Size of the database

Size of the database (number of individuals)

< 500 individuals

Details of the number of individuals

277

Data

Database activity

Data collection completed

Type of data collected	Clinical data
Clinical data (detail)	Medical registration
Details of collected clinical data	Validation of selection criteria ; Information about the study and written consent form ; Demographic and general data ; Disease history ; Bevacizumab treatment ; G8 index and comorbidity index of Charlson, if done ; Response to first-line treatment ; Combined treatments ; First disease progression ; Patient-reported outcomes ; Reason of withdrawal ; Adverse events.
Presence of a biobank	No
Procedures	
Quality procedure(s) used	GCP/GVP
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the referring doctor
Followed pathology	C00-C75 - Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Dedicated website	https://www. Roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only